Consensus $3.24. The company said the change reflects challenging retail environment in the U.S., early wind-down of sale-leaseback program, and lower earnings due to Cencora share sales, offset by execution in pharmacy services and a lower adjusted effective tax rate. The company is also maintaining its U.S. Healthcare adjusted EBITDA view to be breakeven at the midpoint of the guidance range of loss of $50M to gain of $50M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WBA:
- Amazon expands same-day pharmacy delivery to NY and LA, WSJ reports
- Walgreens Boots Alliance price target lowered to $21 from $22 at Morgan Stanley
- Walgreens Boots Alliance price target lowered to $22 from $23 at BofA
- Walgreens Boots Alliance Inc. (WBA) Q2 Earnings Cheat Sheet
- Walgreen Boots call volume above normal and directionally bullish
